ASH 2022 – Shirley D’Sa
Shirley D’Sa discusses the results of the first clinical trial investigating checkpoint inhibition in relapsed/refractory Waldenström’s macroglobulinemia as well as other immunotherapeutic agents or combinations that might be worth investigating in this setting and explains the association of type I cryoglobulinemia with WM, IgM monoclonal gammopathy of undetermined significance or non-Hodgkin Lymphoma.
Here is the full ASH 2022 report.
More posts
Clinical findings with sundry targets in various B-cell malignancies
Clinical findings with sundry targets in various B-cell malignancies AUGMENT: 5-year res
Follicular lymphoma: bispecific and PI3Kδ-targeted approaches
Follicular lymphoma: bispecific and PI3Kδ-targeted approaches Advanced-stage follicular
New approaches in relapsed and refractory DLBCL
New approaches in relapsed and refractory DLBCL Polatuzumab vedotin plus R-ICE Approxi
Chronic lymphocytic leukemia: moving towards new horizons
Chronic lymphocytic leukemia: moving towards new horizons Final analysis of ALPINE: za
Further steps to improve efficacy and safety in acute myeloid leukemia
Further steps to improve efficacy and safety in acute myeloid leukemia Long-term follo
Active monotherapies and combinations in mantle cell lymphoma
Active monotherapies and combinations in mantle cell lymphoma First-line triple combin
